80 F
Mérida
Tuesday, July 5, 2022

Mexico’s Patria vaccine to begin human trials this week

Latest headlines

Carlos Rosado van der Gracht
Carlos Rosado van der Gracht
Born in Mérida, Carlos Rosado van der Gracht is a Mexican/Canadian blogger, photographer and adventure expedition leader. He holds degrees in multimedia, philosophy and translation from universities in Mexico, Canada and Norway. Sign up for the Yucatán Roundup, a free newsletter, which delivers the week's top headlines every Monday.
If all goes well, the Patria vaccine should be available by the end of the year. Photo: Courtesy

Volunteer recruitment has begun for trials of Mexico’s first COVID-19 vaccine candidate.

The Patria vaccine was developed by the Mexican drug manufacturer Avimex in conjunction with several state-run laboratories and Mexico’s national university. 

“Volunteers will be inoculated with the vaccine in the next few days, we expect to see the first batch of preliminary results towards the end of May,” said Mairía Elene Álvaerez of Mexico’s National Science and Technology Council. 

The Patria vaccine could begin to be administered by the end of the year, state health officials said.

Earlier: COVID-19 vaccines for residents in their 50s to begin as early as May

The Patria vaccine works by carrying a specialized gene through a vector. Cells then begin to reproduce “S proteins.” This alerts the body’s immune system to produce antibodies against COVID-19.

It is unclear if the vaccine will require a double dose — such as the Pfizer and Moderna vaccines — or a single dose like the CanSino drug from China. 

Five different vaccines have been approved by Mexican health authorities for use in humans. They are the Pfizer, AstraZeneca, Sinovac, CanSino, and Sputnik V vaccines. 

Cuba is set to become the first Latin American country to produce a viable COVID-19 vaccine. Its Soberana vaccine has now entered the final testing stages and authorities say that it should be ready for human use before the start of summer.

- Advertisement -spot_img

Subscribe Now!

spot_img

More articles